PMID- 36494190
OWN - NLM
STAT- MEDLINE
DCOM- 20230725
LR  - 20230731
IS  - 2573-8348 (Electronic)
IS  - 2573-8348 (Linking)
VI  - 6
IP  - 7
DP  - 2023 Jul
TI  - Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell 
      lung cancer and small cell lung cancer patients: The ToxImmune study.
PG  - e1760
LID - 10.1002/cnr2.1760 [doi]
LID - e1760
AB  - BACKGROUND: Immunotherapy alone or in combination has clearly improved the 
      survival of patients with lung cancer. However, it may also be responsible for 
      adverse events impacting these patients' quality of life. The ToxImmune study 
      aims to identify prognostic factors that can help to predict immune-related 
      adverse events. METHODS: We included all patients aged 18 years and older who had 
      received at least one dose of immune checkpoint inhibitors, with or without other 
      therapy, between June 2015 and December 2020 and were diagnosed with nonsmall 
      cell lung cancer or small-cell lung cancer. Patients' baseline demographic 
      characteristics, biological blood markers, and imaging by PET-scanner were 
      collected from electronic medical records. All adverse events (AEs) and 
      immune-related AEs (irAEs) were recorded (Common Terminology Criteria For Adverse 
      Events V.5.0). RESULTS: Sixty-four patients were included, of whom 60 (94%) 
      presented at least one irAE. The incidence of Common Terminology Criteria for 
      Adverse Events (CTCAE) grade 2 and grade 3-4 was 34% and 8% respectively. Female 
      sex, Primitive Tumor Standardized Uptake Value Max (SUVmax) <5, number of 
      metastases >/=3 and immunotherapy received after the first line were found to be 
      significant risk factors for immune-related adverse events. Based on the number 
      of risk factors, the ToxImmune score predicts the risk of having a grade >/=2 
      adverse event (primitive tumor SUV >/= 5 = 0 vs. primitive tumor SUV <5 = 1, number 
      of metastases <3 = 0 vs. number of metastases >/=3 = 1 and L1 = 0 vs. L1 >/= 1). The 
      incidence of grade >/=2 adverse events was 20%, 55% and 90% with ToxImmune scores 
      0, 1 and = 2 respectively (p = .003). Median progression-free survival (PFS) 
      times were 19.2 months, 6.64 months and 2.63 months for ToxImmune scores 0, 1 
      and = 2 respectively, p = .13. Median overall survival times were 22.6 months, 
      16.4 months and 9.8 months for ToxImmune scores 0, 1 and >/=2 respectively, 
      p = .24. The disease control rate (DRR) was 78% in ToxIummune score 0 group, and 
      50% in ToxImmune score 1 and >/=2 groups (p = .363). CONCLUSION: The ToxImmune 
      score, which is grounded on objective clinical parameters, indicates that cases 
      with a high score had an advanced threat of severe adverse events. The ToxImmune 
      score could therefore be used in clinical practice to identify patients treated 
      for lung cancer with immunotherapy and at risk of severe AE.
CI  - (c) 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
FAU - Difoum, Francoise
AU  - Difoum F
AD  - Clinical Research unit, Military Hospital Begin, Saint-Mande, France.
FAU - Schernberg, Antoine
AU  - Schernberg A
AD  - Clinical Research unit, Military Hospital Begin, Saint-Mande, France.
FAU - Vanquaethem, Helene
AU  - Vanquaethem H
AD  - Department of Internal Medicine, Military Hospital Begin, Saint-Mande, France.
FAU - Picchi, Hugo
AU  - Picchi H
AD  - Department of Medical oncology, Military Hospital Begin, Saint-Mande, France.
FAU - Roy, Audrey Le
AU  - Roy AL
AD  - Department of Medical oncology, Military Hospital Begin, Saint-Mande, France.
FAU - Vuagnat, Perrine
AU  - Vuagnat P
AD  - Clinical Research unit, Military Hospital Begin, Saint-Mande, France.
FAU - Helissey, Carole
AU  - Helissey C
AUID- ORCID: 0000-0002-7774-349X
AD  - Clinical Research unit, Military Hospital Begin, Saint-Mande, France.
AD  - Department of Medical oncology, Military Hospital Begin, Saint-Mande, France.
LA  - eng
PT  - Journal Article
DEP - 20221209
PL  - United States
TA  - Cancer Rep (Hoboken)
JT  - Cancer reports (Hoboken, N.J.)
JID - 101747728
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Small Cell Lung Carcinoma/drug therapy
MH  - Prognosis
MH  - Quality of Life
MH  - *Antineoplastic Agents, Immunological/therapeutic use
PMC - PMC10363797
OTO - NOTNLM
OT  - immune-related adverse events
OT  - immunotherapy
OT  - lung cancer
COIS- The authors declare no conflict of interest with this work.
EDAT- 2022/12/10 06:00
MHDA- 2023/07/25 06:43
PMCR- 2022/12/09
CRDT- 2022/12/09 21:42
PHST- 2022/10/07 00:00 [revised]
PHST- 2022/07/17 00:00 [received]
PHST- 2022/11/27 00:00 [accepted]
PHST- 2023/07/25 06:43 [medline]
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2022/12/09 21:42 [entrez]
PHST- 2022/12/09 00:00 [pmc-release]
AID - CNR21760 [pii]
AID - 10.1002/cnr2.1760 [doi]
PST - ppublish
SO  - Cancer Rep (Hoboken). 2023 Jul;6(7):e1760. doi: 10.1002/cnr2.1760. Epub 2022 Dec 
      9.